| Entry |
|
|---|
| Name |
Disopyramide phosphate (JAN/USP);
Norpace (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C21H29N3O. H3PO4
|
|---|
| Exact mass |
437.208
|
|---|
| Mol weight |
437.4696
|
|---|
| Structure |
     |
|---|
| Activity |
Cardiac depressant [anti-arrhythmic] [DS: H00292]
|
|---|
| Remark |
Same as: Therapeutic category: ATC code: |
|---|
| Comment |
Class I antiarrhythmic agent
|
|---|
| Target |
voltage-gated sodium channel (SCN1A) blocker [HSA: 6323] [KO: K04833]; voltage-gated sodium channel (SCN2A) blocker [HSA: 6326] [KO: K04834]; voltage-gated sodium channel (SCN3A) blocker [HSA: 6328] [KO: K04836]; voltage-gated sodium channel (SCN4A) blocker [HSA: 6329] [KO: K04837]; voltage-gated sodium channel (SCN5A) blocker [HSA: 6331] [KO: K04838]; voltage-gated sodium channel (SCN8A) blocker [HSA: 6334] [KO: K04840]; voltage-gated sodium channel (SCN9A) blocker [HSA: 6335] [KO: K04841] |
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
Transporter: SLC22A3 [HSA: 6581]
|
|---|
| Interaction |
Transporter inhibition: SLC22A1 [HSA: 6580]
 |
|---|
| Structure map |
| Antiarrhythmic drugs | | Sodium channel blocking drugs |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
212 Antiarrhythmic agents
2129 Others
D00637 Disopyramide phosphate (JAN/USP)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C01 CARDIAC THERAPY
C01B ANTIARRHYTHMICS, CLASS I AND III
C01BA Antiarrhythmics, class Ia
C01BA03 Disopyramide
D00637 Disopyramide phosphate (JAN/USP)
USP drug classification [BR:br08302]
Cardiovascular Agents
Antiarrhythmics
Disopyramide
D00637 Disopyramide phosphate (JAN/USP)
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated cation channels
Na+ channel, SCN alpha, NaV1.x
voltage-gated sodium channel (SCN1A) [HSA:6323] [KO:K04833]
Disopyramide [ATC:C01BA03]
D00637 Disopyramide phosphate (JAN/USP)
voltage-gated sodium channel (SCN2A) [HSA:6326] [KO:K04834]
Disopyramide [ATC:C01BA03]
D00637 Disopyramide phosphate (JAN/USP)
voltage-gated sodium channel (SCN3A) [HSA:6328] [KO:K04836]
Disopyramide [ATC:C01BA03]
D00637 Disopyramide phosphate (JAN/USP)
voltage-gated sodium channel (SCN4A) [HSA:6329] [KO:K04837]
Disopyramide [ATC:C01BA03]
D00637 Disopyramide phosphate (JAN/USP)
voltage-gated sodium channel (SCN5A) [HSA:6331] [KO:K04838]
Disopyramide [ATC:C01BA03]
D00637 Disopyramide phosphate (JAN/USP)
voltage-gated sodium channel (SCN8A) [HSA:6334] [KO:K04840]
Disopyramide [ATC:C01BA03]
D00637 Disopyramide phosphate (JAN/USP)
voltage-gated sodium channel (SCN9A) [HSA:6335] [KO:K04841]
Disopyramide [ATC:C01BA03]
D00637 Disopyramide phosphate (JAN/USP)
 |
|---|
| Other DBs |
CAS: 22059-60-5 PubChem: DrugBank: LigandBox: NIKKAJI: |
|---|
| KCF data |
ATOM 30
1 P1b P 35.9712 -15.3016
2 O1c O 37.3683 -15.3074
3 O1c O 35.9655 -16.6987
4 O1c O 34.5741 -15.3016
5 O1c O 35.9655 -13.8986
6 C8x C 25.2790 -16.8457
7 C8x C 25.2790 -18.2076
8 C8x C 26.4584 -18.8885
9 N5x N 27.6379 -18.2076
10 C8y C 27.6379 -16.8457
11 C8x C 26.4584 -16.1647
12 C8x C 29.9967 -18.2076
13 C8y C 29.9967 -16.8457
14 C1d C 28.8173 -16.1647
15 C8x C 31.1762 -18.8885
16 C8x C 32.3556 -18.2076
17 C8x C 32.3556 -16.8457
18 C8x C 31.1762 -16.1647
19 C1b C 28.8173 -14.8028
20 C1b C 29.9988 -14.1207
21 C5a C 26.8208 -15.0752
22 N1a N 26.8208 -13.7133
23 O5a O 25.6650 -15.7548
24 N1c N 29.9988 -12.6240
25 C1c C 31.1623 -11.9521
26 C1c C 28.8034 -11.9337
27 C1a C 27.6325 -12.6097
28 C1a C 28.8036 -10.5810
29 C1a C 32.3174 -12.6190
30 C1a C 31.1624 -10.5812
BOND 30
1 1 2 1
2 1 3 1
3 1 4 1
4 1 5 2
5 6 7 2
6 7 8 1
7 8 9 2
8 9 10 1
9 10 11 2
10 6 11 1
11 12 13 1
12 13 14 1
13 10 14 1
14 12 15 2
15 15 16 1
16 16 17 2
17 17 18 1
18 13 18 2
19 14 19 1
20 19 20 1
21 14 21 1
22 21 22 1
23 21 23 2
24 20 24 1
25 24 25 1
26 24 26 1
27 26 27 1
28 26 28 1
29 25 29 1
30 25 30 1
|
|---|
